Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, November 24, 2010 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced the new corporate name of merged production subsidiary. As announced on...
TOKYO, November, 1, 2010—Astellas Pharma Inc. (TSE: 4503; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it entered into a definitive option agreement with...
Tokyo, October 28, 2010 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) and its US affiliate Astellas US LLC (headquarters: Deerfield, IL;...
Tokyo, October 28, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it submitted a market authorization application for...
Tokyo, October, 25, 2010—Astellas Pharma Inc. (“Astellas”; President and CEO: Masafumi Nogimori) announced that the “Flying Star Fund,” a social contribution fund run by employees, has...
Tokyo and Akita, Japan, September 30, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and UMN Pharma Inc. (“UMN Pharma”; headquarters:...
Zeria Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President and CEO: Sachiaki Ibe; “Zeria”) and Astellas Pharma Inc. (Headquarters: Chuo-ku, Tokyo; President and CEO: Masafumi...
Read more about Announcement of the NDA submission of Z-338 /YM443 for functional dyspepsia in Japan
Tokyo, September 29, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it submitted a market authorization application for...
Osaka and Tokyo, Japan, September 10, 2010 - Ono Pharmaceutical Co., Ltd. (“Ono”; headquarters: Osaka; President and Representative Director: Gyo Sagara) and Astellas Pharma Inc....
Tokyo, Japan, September 8, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced the donation of three high-standard ambulances to local...
Read more about Donation of Ambulances on First-Aid Day (September 9)
Astellas Pharma Inc. and its US subsidiary, Astellas Pharma US, Inc. ("Astellas") and Teva Pharmaceutical USA, Inc. ("Teva") announced today that the three companies have reached an agreement to...
Read more about Astellas and Teva Reached a Settlement Agreement on VESIcare® Patent Case
Japan, May 12, 2010 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called “the Company”) today announced that at the meeting of the Board of...
Read more about Astellas Announces Cancellation of Treasury Stock
Japan, April 28, 2010 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that its US subsidiary, Astellas Pharma US,...
Read more about Astellas Pharma US, Inc. Announces Construction of New Corporate Headquarters
Japan, 1 March 2010 - Astellas Pharma Inc. (“Astellas”; Headquarters: Tokyo, President & CEO: Masafumi Nogimori) today announced that its subsidiary Astellas Pharma US, Inc. (Headquarters:...
Read more about Astellas to Send Additional Relief Effort following Haiti Earthquake
Japan, February 26, 2010 - Astellas Pharma Inc. (“Astellas” Headquarters: Chuo-ku, Tokyo; President & CEO: Masafumi Nogimori) announced today the withdrawal of the application for approval of...
Tokyo, Japan, February 24, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has entered into a license,...
Japan, January 19, 2010 - Astellas Pharma Inc. ("Astellas";Headquarters: Tokyo, President & CEO: Masafumi Nogimori) today announced that it will make a donation of 5 million yen to the Japanese...
Read more about Astellas to Support Relief Efforts following Haiti Earthquake
Tokyo, Japan, January 12, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and AstraZeneca K.K. (headquarters: Tokyo; President and CEO:...
Read more about Launch of Symbicort® Turbuhaler®for the Treatment of Adult Bronchial Asthma in Japan
Japan, December 22, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it submitted an application for market authorization for...
Read more about Application for Orally Disintegrating Tablet YM905 in Japan
Japan, December 14, 2009 – Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that it completed acquisition of...
Tokyo, Japan, December 11, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and AstraZeneca K.K. (headquarters: Tokyo; President and CEO:...
Tokyo, Japan, November 26, 2009 – Pfizer Japan Inc. (“Pfizer”) and Astellas Pharma Inc. (“Astellas”) today announced that combination drug of hypertension treatment and...
Read more about Pfizer and Astellas Announce the Launch of Caduet® Combination Tablets in Japan
Tokyo, Japan, November 26, 2009 – Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that its North American affiliate, Astellas Pharma US, Inc....
Tokyo, Japan, November 5, 2009 -Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has decided to transfer the functions of...
Read more about Transfer of Fermentation and Biotechnology Labs.
Japan, November 5, 2009 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that at the meeting of the Board of...
Read more about Astellas Announces Acquisition of Treasury Stock
Japan, October 26, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it has decided to terminate the development of...
Tokyo, Japan, October 16, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it was granted approval for “myasthenia...
Tokyo, Japan, October 16, 2009 - AstraZeneca K.K. (headquarters: Tokyo; President and CEO: Masuhiro Kato) today announced that it received a Japanese manufacturing and marketing approval for...
Tokyo, Japan, October 7, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that Astellas and Boehringer Ingelheim Pharmaceuticals, Inc. (a US...
Read more about Astellas and Boehringer Ingelheim Reach Settlement with Impax on FLOMAX® Patent Case
Tokyo, Japan, September 25, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that Boehringer Ingelheim Pharmaceuticals, Inc. (“
Read more about ASTELLAS ANNOUNCES EXTENSION OF MARKET EXCLUSIVITY IN THE US FOR FLOMAX® CAPSULES
Tokyo, Japan, September 24, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) and its US affiliate Astellas Pharma US, Inc. (headquarters:...
Read more about ASTELLAS FILED LAWSUIT AGAINST VESICARE® GENERICFOR PATENT INFRINGEMENT IN THE US
Tokyo, Japan, September 2, 2009- Astellas Pharma Inc. (“Astellas”, Headquarters: Chuo-ku, Tokyo; President & CEO: Masafumi Nogimori) announced today that it has established a fund laboratory...
Tokyo, Japan, August 26, 2009 – Pfizer Japan Inc. (“Pfizer”) and Astellas Pharma Inc. (“Astellas”) today announced that the companies have reached a co-promotion agreement for a...
Read more about Pfizer and Astellas Announce Co-promotion Agreement for Caduet® Combination Tablets
Tokyo, Japan, August 21, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that the groundbreaking ceremony for Fermentation...
Tokyo, Japan, August 21, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has decided to reorganize its drug...
Read more about Reorganization of Drug Discovery Research Functions
As stated in the press release issued on August 11, 2009, Astellas Pharma US, Inc. (“Astellas Pharma US”; headquarters: Deerfield, IL), North American affiliate of Astellas Pharma Inc....
Tokyo, Japan, August 11, 2009- Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that its North American affiliate, Astellas Pharma...
Read more about Astellas Announces the Outcome of its Citizen Petition in the US
Tokyo, Japan, August 4, 2009 - AstraZeneca K.K., the Japanese subsidiary of AstraZeneca PLC and Astellas Pharma Inc. (“Astellas”) today announced that AstraZeneca AB (“AstraZeneca”) and...
Follow us
